FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1

Histopathology

Volumn 57, Issue 1, 2010, Pages 73-80

  Hoeller, Sylvia ^a   Schneider, Aurelia ^a   Haralambieva, Eugenia ^b   Dirnhofer, Stephan ^a   Tzankov, Alexandar ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

diffuse large B cell lymphoma; fluorescence in situ hybridization; FOXP1; t(3; 14); tissue microarray

Indexed keywords

ANTHRACYCLINE DERIVATIVE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME GAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRISOMY; TRISOMY 3; CHROMOSOME 3; DNA MICROARRAY; GENE EXPRESSION; GENETICS; GERMINAL CENTER; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; REPRESSOR PROTEINS; TREATMENT OUTCOME;

EID: 77954548070     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03600.x     Document Type: Article

References (27)

1. Lai E, Clark KL, Burley SK, Darnell JE Jr. Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function. Proc. Natl Acad. Sci. USA 1993 90 10421 10423.
2. Hu H, Wang B, Borde M et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 2006 7 819 826.
3. Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl Acad. Sci. USA 2008 105 13520 13525.
4. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 2003 100 9991 9996.
5. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat. Rev. Immunol. 2002 2 920 932.
6. Jais JP, Haioun C, Molina TJ et al. Groupe d'Etude des Lymphomes de l'Adulte. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008 22 1917 1924.
7. Adams H, Tzankov A, Lugli A, Zlobec I. New time-dependent approach to analyze the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J. Clin. Pathol. 2009 62 986 997.
8. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004 104 2933 2935.
9. Barrans SL, Fenton JA, Ventura R, Smith A, Banham AH, Jack AS. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement. Haematologica 2007 92 863 864.
10. Banham AH, Connors JM, Brown PJ et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 2005 11 1065 1072.
11. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur. J. Haematol. 2009 82 364 372.
12. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005 19 652 658.
13. Sagaert X, de Paepe P, Libbrecht L et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J. Clin. Oncol. 2006 24 2490 2497.
14. Goatly A, Bacon CM, Nakamura S et al. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod. Pathol. 2008 21 902 911.
15. Vinatzer U, Gollinger M, Müllauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 2008 14 6426 6431.
16. Haralambieva E, Adam P, Ventura R et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006 20 1300 1303.
17. Fenton JA, Schuuring E, Barrans SL et al. T(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006 45 164 168.
18. Wlodarska I, Veyt E, De Paepe Vandenberghe P et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005 19 1299 1305.
19. Ci W, Polo JM, Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr. Opin. Hematol. 2008 15 381 390.
20. Parekh S, Polo JM, Shaknovich R et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007 110 2067 2074.
21. Otsuki T, Yano T, Clark HM et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. Blood 1995 85 2877 2884.
22. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008 93 193 200.
23. Meier C, Hoeller S, Bourgau C et al. Recurrent numeric aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod. Pathol. 2009 22 476 487.
24. Tzankov A, Schneider A, Hoeller S, Dirnhofer S. Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site. Hum. Pathol. 2009 40 1055 1056.
25. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282.
26. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009 15 5494 5502.
27. Bea S, Zettl A, Wright G et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005 106 3183 3190.